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The gel test: use in the identifica-
tion of unexpected antibodies to
blood group antigens
W.J. JUDD, E.A. STEINER, P.C. KNAFL, AND C. MASTERS
The IgG GEL test was compared with the LISS tube test (Löw and
Messeter’s low-ionic-strength saline) for antibody identification. The
suitability of red blood cells (RBCs) pretreated with ficin, dithiothre-
itol (DTT), or chloroquine diphosphate (CDP) also was assessed for
use in the GEL test. In addition, time-in-motion studies were per-
formed comparing GEL (12 panels per batch) with polyethylene gly-
col (PEG) tube tests (3 panels per batch). In 57 antibody identifica-
tion studies, there were 63 GEL+ LISS+, 2 GEL+ LISS–, and 6
GEL–LISS+ antibodies. Among the GEL+ LISS+ antibodies were 19
that yielded stronger reactions in GEL than in LISS; by virtue of their
specificity, 14 of these are considered potentially significant: D, 5 E,
2 e, 2 Jka , 2 S, K, and Fya. There were 38 antibodies that yielded
equivalent results by both methods, including 31 that are considered
potentially significant. Of six antibodies with significantly greater
reactivity in LISS, there were three anti-Rh and three that are consid-
ered harmless with respect to transfusion management. The two
GEL+ LISS– antibodies (anti-Jkb) were potentially significant. GEL–
LISS+ reactions involved only harmless antibodies. Of the 50 anti-
bodies of potential significance, GEL yielded equivalent or superior
results in 47 (94%) instances. Additionally, GEL failed to detect 6 of
21 harmless antibodies. Expected results were obtained with normal
serum or plasma and antibodies of known specificity in tests with
RBCs treated with ficin, DTT, or CDP. Hands-on-time required for
each GEL panel was 2 to 21/2 minutes compared with 12 minutes for
PEG. These data document the suitability of GEL for use in antibody
identification studies. Immunohematology 1998;14:59–62.
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New technologies such as the IgG GEL test1 require
crossover validation before implementation. Currently,
there are no published reports from U.S. facilities that
compare the use of GEL with conventional tube tech-
nologies in the identification of unexpected antibodies.
Results of our crossover validation study for antibody
detection by GEL have been described elsewhere.2 In
this present report, we document our findings when
comparing GEL with our routine antibody identification
procedure that is based on the low-ionic-strength saline
(LISS) procedure of Löw and Messeter.3 We also present
data establishing the suitability of GEL for use with both
enzyme-treated and chemically modified red blood cells
(RBCs), as well as the results of time-in-motion studies
comparing GEL with polyethylene glycol (PEG) tube
tests.4
Materials and Methods
An ID-Micro Typing System™ for performing the IgG
GEL test was obtained from Ortho Diagnostic Systems
Inc. (Raritan, NJ). GEL tests were set up and graded as
recommended by the manufacturer.However, in our lab-
oratory, reactions in GEL were read using an illuminated
view box,and doubtful reactions were evaluated using a
hand-held magnification lens.
LISS tests were performed by incubating one volume
(0.1 mL) of 2% reagent RBCs in LISS (Löw and Messeter’s
formulation,3 Immucor,Inc.,Norcross,GA) with an equal
volume of patient’s serum. The reactants were not
warmed to 37°C before mixing. Incubation was for 15
minutes at 37°C, after which the tests were centrifuged
and examined for agglutination and hemolysis.The RBCs
were then washed × 4 with sodium chloride before test-
ing with polyclonal (rabbit) anti-IgG (Ortho). Reactions
were read macroscopically with the aid of an illuminat-
ed concave mirror and graded and scored as described
previously.5 All negative antiglobulin tests were verified
with IgG-coated RBCs (Immucor).
For comparative antibody identification studies
between GEL and LISS, group O reagent RBCs were
either from Gamma Biologicals, Houston,TX; Immucor;
or Organon Teknika Corp., Durham, NC.The same RBC
samples were used for both GEL and LISS. Samples used
for GEL testing were predominantly from EDTA-antico-
agulated blood (to reduce interference from fibrin);
serum was used for LISS. Comparative studies were per-
formed on samples selected at random on patients with
positive LISS tests for unexpected antibodies encoun-
tered during pretransfusion testing. Technologists per-
forming identification studies by GEL were not privy to
the findings by LISS.
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Results by GEL were compared with those by LISS.
Discrepancies were evaluated by repeat testing by both
methods; some were investigated by additional tube
tests using room-temperature incubation, polyspecific
antiglobulin serum, ficin-treated RBCs, or PEG.4 ,5
In other tests, selected donor RBCs were treated with
either ficin, dithiothreitol (DTT), or chloroquine diphos-
phate (CDP), as described elsewhere.5 These were pre-
pared and used by GEL according to the manufacturer’s
recommendations for antibody detection with untreated
RBCs. Sera or plasmas tested against the treated RBCs
were from our routine caseload; some had been stored
frozen at –70°C.
For time-in-motion studies, GEL panels were done in
batches of 12.Both hands-on and throughput times were
measured6 and compared with those required to per-
form three panels by PEG. The latter were done with
commercially available PeG® (Gamma), as described by
the manufacturer. Four technologists performed a total
of 10 timings for each batch method. Each panel con-
sisted of 11 reagent RBC samples and an autologous con-
trol.Times that are constant for both methods (e.g., sam-
ple centrifugation) were not measured.
Results
The results of GEL and LISS tests on 71 antibodies
from 57 samples are compared in Table 1. There were 63
GEL+ LISS+,2 GEL+ LISS–,and 6 GEL– LISS+ antibodies.
Among the GEL+ LISS+ antibodies were 38 GEL = LISS,
19 GEL > LISS, and 6 GEL < LISS antibodies (where =
denotes no observed difference, > or < denotes an
observed difference of at least one grade of reactivity
between the two methods).By virtue of their specificity,
31 of 38 GEL = LISS antibodies are considered potential-
ly significant with respect to transfusion management.
Of 19 GEL > LISS antibodies, 14 are potentially signifi-
cant, whereas 3 of 6 GEL  < LISS antibodies are clinically
important.The 2 GEL + LISS– antibodies (anti-Jkb) were
both potentially significant. The remaining GEL > LISS,
GEL < LISS, and the 6 GEL– LISS+ antibodies are consid-
ered harmless with respect to transfusion management
or of uncertain clinical significance.There were 8 anti-
bodies (3 E, M, Lea, Leb, 2 cold-auto) that reacted only as
direct agglutinins in LISS; of these, the 3 anti-E and the
Lea were detected by GEL.
Table 2 compares the results of GEL tests with
untreated and ficin-treated RBCs. The anticipated
enhancement of reactivity was seen with Rh and Kidd
system antibodies, and the expected loss of reactivity
was observed with antibodies to protease-sensitive anti-
gens (e.g., Fy, MNS).The reactivity of other antibodies in
GEL was variably affected by pretreatment of RBCs with
ficin, consistent with their reported reactivity in tube
tests.
In other tests, we evaluated the specificity of GEL
with ficin-treated RBCs (data not shown in Table 2). Of
70 serum or plasma samples from patients with negative
screening tests for unexpected antibodies by LISS tube
technique, 61 were nonreactive with ficin-treated RBCs
by GEL. The nine reactive samples included three that
contained enzyme-dependent panagglutinins;one exam-
ple each of anti-HI, -E,and -Lea; two that exhibited no dis-
cernible specificity; and one sample that yielded a spuri-
Table 1. Comparison of antibody identification studies by GEL and by LISS
Results Wanted* Unwanted* Total
GEL = LISS† 3 D, 3 C, c, 2 E, 2 cE, f, Cw RhIG‡; M; cold-auto 38
7 Jka; 2 S; 5 K; 4 Fya 4 warm-auto
GEL > LISS§ D, 5 E(3| ), 2 e M; Lea| ; 2 warm-auto 19
2 Jk a; 2 S; K; Fya NOID¶
GEL < LISS** 2 E, D M; P1; cold-auto 6
GEL+ LISS– 2 Jkb 2
GEL– LISS+ M| ; N; Lea, Leb| 6
2 cold-auto|
Total 50 21 71
* Presumed significance based on specificity and derived from clinical
experience with respect to transfusion of incompatible blood
† Reactions by GEL equal to those by LISS-IgG
‡ Anti-D passively acquired from Rh immune globulin
§ Reactions by GEL stronger than those in LISS-IgG by at least one graded
reaction strength
| Antibodies detected by LISS as direct agglutinins at 37°C; nonreactive with  
anti-IgG
¶ No identification; both positive and negative tests seen; no discernible
specificity
**Reactions by GEL weaker than those in LISS-IgG by at least one graded
reaction strength
Table 2. Effect of ficin treatment of red blood cells* on blood group anti-
body reactivity in GEL tests
Anti- n† Not Ficin- Not Ficin-
Treated Treated Anti- n† Treated Treated
D 2 10‡ 12 Fya 3§ 8.7 0
C 2 11 12 Fyb 2§ 9 0
c 3 10.7 12 M 1§ 8 0
E 3 5.3 11.7 N 1§ 9 0
e 1 10 12 S 2§ 10.5 1
Jka 3 6.7 9.7 s 2§ 7.5 0
Jkb 2 6.5 10 Ch 2 8 0
Jk3 4 7.5 9.5 Rg 1 3 0
K 3 7.3 9.7 JMH 1 8 0
k 1 8 10 Yta 2 9 6.5
Kpb 1 10 12 Lub 1 8 5
Jsb 1 10 10 Lu17 1 5 4
* Each antibody tested against same single-dose red blood cell sample,  both
treated and untreated, except as otherwise indicated.§ For antibodies to
high-prevalence antigens, presumed double-dose red blood cells were
used
† Number of samples tested
‡ Values represent average reaction score5
§ For these antibodies, single-dose untreated and apparent double-dose
ficin-treated red blood cells were used
Gel test for antibody identification
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ously positive reaction.
The results of tests with DTT- and CDP-treated RBCs
by GEL are shown in Table 3. DTT-treated RBCs gave the
expected negative or weaker reactions with antibodies
to antigens known to be sensitive to thiol reagents (e.g.,
Kell system,JMH,Yta).All other specificities studied react-
ed equally well with both untreated and DTT-treated
RBCs in GEL.Three examples of anti-Bg were reactive in
GEL with untreated RBCs and gave the anticipated nega-
tive results with CDP-treated RBCs. All other antibodies
tested in GEL reacted with CDP-treated RBCs to the same
degree as untreated RBCs. No unwanted positive tests
were encountered with either DTT-treated RBCs (n = 64)
or CDP-treated RBCs (n = 22;data not shown in Table 3).
Table 4 shows the results of time-in-motion studies.
Hands-on time for GEL was 25 minutes (batch of 12 pan-
els) compared with 37 minutes for PEG (batch of 3 pan-
els).There was no difference in the throughput times for
the two batch methods. However, the time taken to pre-
pare reagent RBCs for use in GEL is excluded from Table
4, because cell preparation for GEL can be performed
once daily rather than for each batch. In our studies we
found that it takes 5 minutes to prepare sufficient RBCs
to perform up to five batches of 12 panels by GEL per
day.Given this information,and using the batch numbers
described, the hands-on time required for each GEL
panel equals 2 to 21/2 minutes, compared with 12 min-
utes for PEG.
Table 3. Effect of chemical treatment of red blood cells* on blood group 
antibody reactivity in GEL tests
Not DTT†- CDP‡- Not DTT- CDP-
Anti- Treated Treated Treated Anti- Treated Treated Treated
K 8§,5,9|| 0,0,0¶ 8 JMH 8 0 8
k 8 0 8 Yta 8,10 0,0 8,9
Kpb 10 4 11 Fya 8 8 8
Jsb 10 0 9 Fyb 8 8 8
D 10 10 11 M 8 8 8
C 12 11 10 N 9 9 NT**
c 10 8 8 S 10 10 10
E 11 11 11 s 4 4 3
e 10 10 10 Lub 8 8 8
Jka 88 8 Lu17 5 5 5
Jkb 58 5 Ch 8,8 9,8 8,8
Jk3 8,8,8,8 10,8,6,8 6 Rg 3 3 3
Bg 4,4,3 NT 0,0,0
* Each antibody tested against same single-dose red blood cell sample, both
treated and untreated, except as otherwise indicated.¶ For antibodies to




§ Values represent average reaction score 5
||Multiple results represent test scores obtained with different examples of
these antibodies; underlining indicates samples to be compared
¶ For three anti-K, single-dose untreated and apparent double-dose DTT-
treated red blood cells were used 
**Not tested
Table 4. Results of time-in-motion* studies comparing GEL with PEG
GEL Tests—12 panels† TIME‡ PEG Tube Tests—3 panels
label cards 1 label tubes
2
prepare patient RBCs × 12 3
4
5 prepare patient RBCs × 3
6
add panel RBCs × 12 7 add panel RBCs ×  3
8
9
10 add patient RBCs × 3
add patient RBCs × 12 11 add serum for Patient 1
12 add PEG to tests for Patient 1
13 incubate tests for Patient 1
add patient sera × 12 14
15
16
17 add serum for Patient 2
place cards in incubator 18 add PEG to tests for Patient 2
19 incubate tests for Patient 2
20
21
22 add serum for Patient 3
23 add PEG to tests for Patient 3









centrifuge cards 33 add AHG|| to tests for Patient 1
and spin
34 wash tests for Patient 2
35 read tests for Patient 1
36
37
38 add AHG to tests for Patient 2
and spin
39 wash tests for Patient 3
40 read tests for Patient 2
41
42
43 add AHG to tests for Patient 3
and spin
read and record reactions 44





* Shading denotes hands-on time
† Excludes time taken to prepare panel red blood cells for GEL (see text)
‡ Average of 10 separate timings
§ PEG tube tests washed ×  3
||Anti-human globulin
¶ Time taken to read PEG panels includes time taken to verify negative tests
with IgG-coated red blood cells
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Discussion
Data presented in this article demonstrate the suit-
ability of GEL for use in antibody identification studies.
Potentially significant antibodies are clearly identified,
falsely positive results are not obtained with samples
yielding negative antibody detection tests, and the caus-
es of positive antibody detection tests are readily eluci-
dated. Moreover, GEL detected two potentially signifi-
cant antibodies not reactive by LISS and failed to detect
six harmless antibodies that were reactive in LISS.
Although LISS gave stronger reactions than GEL with
three potentially significant Rh antibodies,nine harmless
antibodies were either solely reactive in LISS or gave
stronger reactions in LISS than in GEL. According to
these results, GEL is equal to or better than LISS for rou-
tine antibody identification studies.
GEL is also suitable for use with RBCs pretreated with
ficin, DTT, or CDP, as evidenced by (1) the absence of
change in reactivity with antibodies to antigens that are
not affected by these treatments; (2) the expected
enhanced reactions of ficin-treated RBCs with Rh and Jk
antibodies; (3) the expected loss of reactivity with anti-
bodies to antigens known to be denatured by ficin,DTT,
or CDP; and (4) the fact that treated RBCs did not yield
unexpected reactions in GEL to any greater extent than
we have experienced in tube tests. In addition,tests used
in the investigation of serologic problems, such as inhi-
bition studies and tests of eluates and adsorbed serum,
can be performed successfully.7 Our experience in these
and similar regards is limited (data not presented), but
RBCs recovered from samples stored in glycerol at 
–70°C5 can be utilized in GEL. Eluates prepared by
organic solvents or by the freeze–thaw technique5 can-
not be tested by GEL because of contamination with
hemoglobin. Furthermore, the sensitivity of GEL for IgG
autoantibodies may necessitate more extensive adsorp-
tion than is required for some tube tests.
The results of time-in-motion studies clearly demon-
strate the increase in productivity that can be achieved
using GEL technology for antibody identification.
Although the workload in most laboratories does not
permit testing in batches as large as those we used, it
should be appreciated that batch testing of three sam-
ples by GEL entails about one-third of the hands-on time
required to test the same samples by PEG.
Gel column technology provides other advantages
over traditional tube testing.1,7 The stability of reactions
allows for repeated review of test results by multiple
technologists. GEL reactions can be graded more objec-
tively than those in tube tests, and the use of standard-
ized volumes of reactants enhances test reproducibility
among laboratory staff.All of these advantages serve to
facilitate the interpretation of serologic observations
encountered in antibody identification studies.
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